PBI-4050 sodium salt
Modify Date: 2024-01-10 14:57:42
PBI-4050 sodium salt structure
|
Common Name | PBI-4050 sodium salt | ||
|---|---|---|---|---|
| CAS Number | 1254472-97-3 | Molecular Weight | 228.263 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C13H17NaO2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PBI-4050 sodium saltPBI-4050 acts as an agonist for GPR40 and as an antagonist or inverse agonist for GPR84. |
| Name | PBI-4050 |
|---|---|
| Synonym | More Synonyms |
| Description | PBI-4050 acts as an agonist for GPR40 and as an antagonist or inverse agonist for GPR84. |
|---|---|
| Related Catalog | |
| Target |
GPR40, GPR84[1] |
| In Vivo | PBI-4050, a synthetic analogue of a medium–chain length fatty acid, binds to FFA receptor 1 (FFAR1/GPR40) and GPR84. To determine the potential role of PBI-4050 on diabetic kidney disease, The accelerated model of type 2 diabetic nephropathy, eNOS-/- db/db mice are utilized. Mice are treated with either vehicle or PBI-4050 (100 mg/kg) by daily gavage from 8-20 weeks of age. eNOS-/- db/db mice are moderately hypertensive, and PBI-4050 has no effect on blood pressure. Furthermore, compared with vehicle-treated mice, which exhibit a decrease in glomerular filtration rate (GFR) from 8-20 weeks, PBI-4050 preserves GFR. Podocyte number per glomerulus section markedly decreases from 8-20 weeks of age in vehicle-treated mice, while PBI-4050 treatment significantly slows this loss[1]. |
| Animal Admin | Mice[1] Type 2 diabetes eNOS-/- db/db mice on the BKS background are used. Genotyping is performed by PCR. A subset of eNOS-/- db/db male mice (8 weeks old) are randomized to 2 groups. One group is treated with PBI-4050 (100 mg/kg/day, n=10) , and the other group receive vehicle (water, n=12). Both PBI-4050 and water are given via daily gavage from 8-20 weeks. Mice are euthanized at 20 weeks of age. The second set of eNOS-/- db/db male mice are divided into 4 groups (8 mice in each group): vehicle (water), PBI-4050 (100 mg/kg/day), Captopril (0.75 mg/mL in drinking water), and PBI-4050 plus captopril. The treatment is begun at 16 weeks and ended at 24 weeks. The third set of eNOS-/- db/db male mice is divided into 2 groups (8 mice in each group): vehicle (water) and PBI-4050 (100 mg/kg/day). The treatment begins at 16 weeks and lasts up to 30 weeks or until death[1]. |
| References |
| Molecular Formula | C13H17NaO2 |
|---|---|
| Molecular Weight | 228.263 |
| Exact Mass | 228.112625 |
| Benzeneacetic acid, 3-pentyl-, sodium salt (1:1) |
| R05571KE07 |
| Sodium (3-pentylphenyl)acetate |